ST Pharm Co.,Ltd.

KOSDAQ 237690.KQ

ST Pharm Co.,Ltd. Operating Income for the year ending December 31, 2023: USD 23.84 M

ST Pharm Co.,Ltd. Operating Income is USD 23.84 M for the year ending December 31, 2023, a 69.01% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.
  • ST Pharm Co.,Ltd. Operating Income for the year ending December 31, 2022 was USD 14.10 M, a 202.08% change year over year.
  • ST Pharm Co.,Ltd. Operating Income for the year ending December 31, 2021 was USD 4.67 M, a 127.03% change year over year.
  • ST Pharm Co.,Ltd. Operating Income for the year ending December 31, 2020 was USD -17.27 M, a 24.96% change year over year.
  • ST Pharm Co.,Ltd. Operating Income for the year ending December 31, 2019 was USD -23.02 M, a -64.56% change year over year.
Key data
Date Operating Income EBIT EBITDA Net Income
Market news
Loading...
KOSDAQ: 237690.KQ

ST Pharm Co.,Ltd.

CEO Mr. Geun-Jo Im Ph.D.
IPO Date June 23, 2016
Location South Korea
Headquarters MSA Building
Employees 566
Sector Health Care
Industries
Description

ST Pharm Co. Ltd., a contract development manufacturing organization, provides products for pharmaceutical and non-pharmaceutical area in South Korea. The company offers chemistry manufacturing control (CMC) services, which includes analytical method development; in-house reference standard testing; analytical method qualification/validation; analytical characterization; and CMC documentation. It also provides oligonucleotide based products, such as antisense, siRNA, miRNA, aptamer, CpG, decoy, and other products; and monomer/phosphoramidite. In addition, the company offers generic APIs for anti-cancer, anti-coagulant, anti-fungal, anti-hyperlipidemia, anti-hypertensive, anti-tuberculosis, asthma, COPD, cough suppressant, diabetes mellitus, epilepsy, hepatitis B, and erectile dysfunction medicines, as well as MRI contrast agents. Further, it provides 2nd battery, electronic materials, and polymer catalysts. The company was formerly known as Samchully Pharmaceutical Company., Ltd. ST Pharm Co. Ltd. was founded in 1983 and is based in Seoul, South Korea.

Similar companies

196170.KQ

ALTEOGEN Inc.

USD 209.72

3.60%

207940.KS

Samsung Biologics Co.,Ltd.

USD 698.37

1.93%

068270.KS

Celltrion, Inc.

USD 125.83

1.12%

006280.KS

Green Cross Corporation

USD 108.37

-2.33%

StockViz Staff

January 15, 2025

Any question? Send us an email